Skip to main content
AmigoFish

From Basel: TOLREMO Therapeutics is working on cancer resistance - the company believes is targeting CBP/p300 just stared phase 1 data at World Lung

From BiotechTV - News · · 7 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

CEO Stefanie Fluckiger-Mangual describes the rationale for targeting CPB/p300 and walks us through TOLREMO's recently presented phase 1 data, which had a clean safety profile and showed evidence of anti-tumor activity.

Back to BiotechTV - News · Report a problem